闭环胰高血糖素系统治疗减重术后低血糖的随机双盲安慰剂对照试验
该双盲安慰剂对照交叉试验纳入12例减重术后低血糖患者,评估闭环葡萄糖响应自动胰高血糖素输注系统减少严重低血糖的效果。结果显示,与安慰剂相比,胰高血糖素组需要救援葡萄糖和发生严重低血糖(<55 mg/dL)的人数更少,最低血浆葡萄糖更高,且无反应性高血糖。
要点
- 闭环系统可预测低血糖并自动输注胰高血糖素。
- 胰高血糖素组严重低血糖和救援需求均少于安慰剂组。
- 未观察到反应性高血糖,仅输注部位短暂不适。
核心结论
- CGM引导的闭环救援系统能检测即将发生的低血糖并输注胰高血糖素,减少减重术后低血糖患者的严重低血糖。
研究设计与样本
- 双盲、安慰剂对照、交叉试验,纳入12例减重术后低血糖患者(11女/1男,年龄52±2岁,术后8±1年)。
- 系统由CGM(Dexcom)驱动贴片输注泵(Insulet),输注液体研究用胰高血糖素(Xeris)或安慰剂,算法触发最多2剂(胰高血糖素300/150 μg或等体积安慰剂)。
主要发现
- 7例患者在安慰剂后需要救援葡萄糖,而胰高血糖素后不需要(P = .008)。
- 5例患者在安慰剂后发生严重低血糖(<55 mg/dL),而胰高血糖素后未发生(P = .03)。
- 胰高血糖素组最低血浆葡萄糖高于安慰剂组(67 ± 3 vs 59 ± 2 mg/dL,P = .004)。
- 输注胰高血糖素后30分钟血浆胰高血糖素升高(1231 ± 187 vs 16 ± 1 pg/mL,P = .001)。
- 未发生反应性高血糖;输注部位短暂不适在胰高血糖素组11/12例、安慰剂组10/12例报告。
关键数值与推荐
- 算法触发时传感器葡萄糖为114 ± 7 vs 121 ± 5 mg/dL(P = .39)。
- 血浆葡萄糖<55 mg/dL或神经低血糖时给予救援葡萄糖。
临床怎么用
- 该闭环系统可作为减重术后低血糖的救援治疗,减少严重低血糖事件。
局限性
- 样本量小(12例完成者),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postbariatric hypoglycemia (PBH) can threaten safety and reduce quality of life. Current therapies are incompletely effective. METHODS: Patients with PBH were enrolled in a double-blind, placebo-controlled, crossover trial to evaluate a closed-loop glucose-responsive automated glucagon delivery system designed to reduce severe hypoglycemia. A hypoglycemia detection and mitigation algorithm was embedded in the artificial pancreas system connected to a continuous glucose monitor (CGM, Dexcom) driving a patch infusion pump (Insulet) filled with liquid investigational glucagon (Xeris) or placebo (vehicle). Sensor/plasma glucose responses to mixed meal were assessed during 2 study visits. The system delivered up to 2 doses of study drug (300/150 μg glucagon or equal-volume vehicle) if triggered by the algorithm. Rescue dextrose was given for plasma glucose <55 mg/dL or neuroglycopenia. RESULTS: Twelve participants (11 females/1 male, age 52 ± 2, 8 ± 1 years postsurgery, mean ± SEM) completed all visits. Predictive hypoglycemia alerts prompted automated drug delivery postmeal, when sensor glucose was 114 ± 7 vs 121 ± 5 mg/dL (P = .39). Seven participants required rescue glucose after vehicle but not glucagon (P = .008). Five participants had severe hypoglycemia (<55 mg/dL) after vehicle but not glucagon (P = .03). Nadir plasma glucose was higher with glucagon vs vehicle (67 ± 3 vs 59 ± 2 mg/dL, P = .004). Plasma glucagon rose after glucagon delivery (1231 ± 187 vs 16 ± 1 pg/mL at 30 minutes, P = .001). No rebound hyperglycemia occurred. Transient infusion site discomfort was reported with both glucagon (n = 11/12) and vehicle (n = 10/12). No other adverse events were observed. CONCLUSION: A CGM-guided closed-loop rescue system can detect imminent hypoglycemia and deliver glucagon, reducing severe hypoglycemia in PBH. CLINICAL TRIALS REGISTRATION: NCT03255629.
引用
- Mulla CM, Zavitsanou S, Laguna Sanz AJ, et al. A Randomized, Placebo-Controlled Double-Blind Trial of a Closed-Loop Glucagon System for Postbariatric Hypoglycemia. J Clin Endocrinol Metab. 2020. PMID: 31714583. doi:10.1210/clinem/dgz197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。